Clinical-stage biotechnology company focused on advancing LAM-001, an investigational inhaled formulation of rapamycin (an mTOR inhibitor), for multiple pulmonary diseases. Formerly Quince Therapeutics, the company relaunched under the IRulya name in October 2026 following its merger with Orphai Therapeutics, and relocated its headquarters from South San Francisco, California to New Haven, Connecticut.
Common stock begins trading on the Nasdaq Capital Market under the ticker IRLA
Quince Therapeutics has relaunched as IRulya Therapeutics, rebranding around an inhaled pulmonary-disease pipeline following its merger with Orphai Therapeutics, alongside a new C-suite and a move of its Nasdaq listing.